This prospective, randomized, controlled trial in patients with long-term type 2 diabetes on high cardiovascular risk under the conditions of stable insulin treatment reveals significant improvements with increased levels for biomarkers of lowgrade inflammation, insulin resistance, and associated CV risk factors, regarding the add-on therapy with pioglitazone and the combination of pioglitazone with metformin. This evidence concerns the gene INS and type 2 diabetes mellitus.